Get the Stockscreener App
12.93
0.56%
0.08
Alvotech stock is traded at $12.93, with a volume of 56,809.
It is up +0.56% in the last 24 hours and down -1.36% over the past month.
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.
See More
Previous Close:
$12.85
Open:
$12.81
24h Volume:
56,809
Relative Volume:
0.41
Market Cap:
$3.87B
Revenue:
$391.87M
Net Income/Loss:
$-441.45M
P/E Ratio:
-6.9892
EPS:
-1.85
Net Cash Flow:
$-301.21M
1W Performance:
+1.59%
1M Performance:
-1.36%
6M Performance:
+17.37%
1Y Performance:
-17.22%
1-Day Range:
$12.81
$12.99
1-Week Range:
$12.04
$12.99
52-Week Range:
$9.15
$18.00
Alvotech Stock (ALVO) Company Profile
Compare ALVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
12.92 | 3.87B | 391.87M | -441.45M | -301.21M | -1.85 |
|
ZTS
Zoetis Inc
|
171.42 | 78.56B | 9.15B | 2.43B | 2.31B | 5.32 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.54 | 43.15B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
9.545 | 43.00B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.72 | 19.59B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
123.16 | 15.24B | 2.24B | 385.90M | 440.10M | 3.73 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Upgrade | Citigroup | Sell → Neutral |
| Sep-21-23 | Initiated | Barclays | Equal Weight |
| Sep-07-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-06-22 | Downgrade | Citigroup | Buy → Sell |
| Jul-26-22 | Initiated | Citigroup | Buy |
View All
Alvotech Stock (ALVO) Latest News
Alvotech (NASDAQ:ALVO) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat
Alvotech (NASDAQ:ALVO) Shares Gap DownTime to Sell? - MarketBeat
Alvotech (NASDAQ:ALVO) Short Interest Update - MarketBeat
Tempus Wealth Planning LLC Makes New Investment in Alvotech (NASDAQ:ALVO) - MarketBeat
China Universal Asset Management Co. Ltd. Purchases Shares of 56,576 Alvotech (NASDAQ:ALVO) - MarketBeat
Alvotech (NASDAQ:ALVO) Shares Gap UpStill a Buy? - MarketBeat
FDA accepts Alvotech, Teva's BLAs for Simponi biosimilars - Drug Store News
Short Interest in Alvotech (NASDAQ:ALVO) Rises By 244.2% - MarketBeat
Alvotech Breaks Below 200-Day Moving AverageNotable for ALVO - Nasdaq
FDA accepts Teva, Alvotech BLAs for Simponi biosimilars - MSN
Alvotech And Teva Claim First US Golimumab Filing - News & Insights
Why IMAC Holdings Shares Are Trading Higher By Over 108%; Here Are 20 Stocks Moving Premarket - Benzinga
Alvotech and Teva Announce Filing Acceptance of U.S. - GlobeNewswire
FDA accepts Teva, Alvotech BLAs for Simponi biosimilars (TEVA:NYSE) - Seeking Alpha
FDA Accepts Alvotech’s Biosimilar to Simponi (Golimumab) for Review - Contract Pharma
FDA Accepts Alvotech’s Biosimilar Applications for Review - TipRanks
Alvotech and Teva Pharmaceuticals Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, A Proposed Biosimilar to Simponi® and Simponi Aria® - Marketscreener.com
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab) - The Korea Bizwire
Alvotech og Teva tilkynna að FDA hefur tekið til umsagnar - GlobeNewswire
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab) - GlobeNewswire Inc.
Alvotech's (NASDAQ:ALVO) largest shareholders are private equity firms with 34% ownership, private companies own 31% - Yahoo Finance
Private equity firms account for 34% of Alvotech's (NASDAQ:ALVO) ownership, while private companies account for 31% - Simply Wall St
J&J stands by sales growth ambitions—and points to potential Tremfya boon—as Stelara biosimilars take hold - FiercePharma
Alvotech (NASDAQ:ALVOW) Stock Price Down 1.3% – Here’s What Happened - Defense World
JB Hunt Transport Posts Weak Earnings, Joins JetBlue Airways And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Why Versus Systems Shares Are Trading Higher By Around 71%; Here Are 20 Stocks Moving Premarket - Benzinga
Has Alvotech (ALVO) Outpaced Other Medical Stocks This Year? - MSN
Alvotech : Transactions of Managers and Closely Associated Persons - Marketscreener.com
Alvotech : Managers' transactionsALVOTECH -January 15, 2025 at 04:03 pm EST - Marketscreener.com
Applied Digital, Vericel, Calavo Growers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Alvotech (NASDAQ:ALVO) Sees Large Growth in Short Interest - MarketBeat
Geode Capital Management LLC Increases Stock Position in Alvotech (NASDAQ:ALVO) - Defense World
Alvotech birtir fjárhagsdagatal fyrir árið 2025 - GlobeNewswire
Alvotech Eyes Growth As Product Revenue Soars And New Launches ApproachWill The Stock Follow? - RTTNews
Are Medical Stocks Lagging Alvotech (ALVO) This Year? - Yahoo Finance
Alvotech Joins Nasdaq Biotechnology Index, Boosting Industry Presence - TipRanks
Alvotech : Added to Nasdaq Biotech Index Effective Monday December 23, 2024 Form 6 K - Marketscreener.com
Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024 - The Manila Times
Alvotech Secures Coveted Spot in Nasdaq Biotechnology Index Following Strong Market Performance - StockTitan
ALVOAlvotech Ordinary Shares Latest Stock News & Market Updates - StockTitan
Wall Street Analysts Believe Alvotech (ALVO) Could Rally 39.83%: Here's is How to Trade - MSN
Alvotech's SWOT analysis: biosimilar powerhouse stock faces b2b model challenges - Investing.com
Alvotech Stock (ALVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.89%
3.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):